SOHO 2021 | Optimizing post-transplant outcomes
Aaron Logan, MD, PhD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, describes post-transplant complications in acute lymphoblastic leukemia (ALL) and optimizing patient outcomes. Monitoring measurable residual disease (MRD) prior to and after transplant and to intervene accordingly to enhance post-transplant outcomes and infections can be managed significantly well with the current standard of care and with prophylaxis use to prevent infections. There are additionally several methods of management for graft-versus-host disease (GvHD) such as the immunological manipulation of the graft to favor graft-versus-leukemia effect. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
